Payers

Indigenous cardiovascular inequity is not a data gap. It is a policy failure

Menopause is a cardiometabolic checkpoint. Health systems still treat it like a hormone debate

MS Regulators Are No Longer Reading the Same Risk

Cardiology has too many dashboards. The danger is forgetting the patient

GLP-1 drug choice now affects cardiovascular outcomes. Access and reimbursement rules have not caught up

Europe Opens the SMA Gene-Therapy Door Wider

Pregnancy complications demand long-term cardiovascular care

MENA’s cardiometabolic crisis is a stability issue

Global cardiovascular policy shifts accelerate, but diverging strategies expose uneven progress
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
